Patent · US Active

Stabilized formulations of CNS compounds

US11077114B2 · kind B2 · utility

0Cited by

8References

28Claims

0Family size

Assignee

Supernus Pharmaceuticals, Inc. · US

Inventors

Rong-Kun Chang · Rockville, US
Michael L. Vieira · Gaithersburg, US
Likan Liang · Wheeling, US
Padmanabh P. Bhatt · Rockville, US
Austin B. Huang · Potomac, US
Sachin V. Patel · Round Lake, US

Key dates

Filing date	Oct 30, 2018
Grant date	Aug 3, 2021
Priority date	—
Expiry date	Oct 30, 2038

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K9/1635
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Formulations of molindone having superior stability and methods of administering same are provided. The formulations may be immediate, modified, or otherwise delayed release formulations of molindone.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.